Your Blood Count Already Tracks IBD Activity: What a 2026 Systematic Review Found About RDW

If you have inflammatory bowel disease, you have almost certainly had a complete blood count at some point in your care. It is one of the most requested routine tests in medicine. Your report lists haemoglobin, white cells, platelets, and a handful of other values. One of those values is called red cell distribution width, or RDW. You may never have noticed it, or been told what it means. A 2026 systematic review and meta-analysis suggests that it has been worth paying attention to all along.

What RDW Actually Measures

Red cell distribution width is not a count of how many red blood cells you have. It is a measure of how much variation there is in their size. In a healthy state, red blood cells are fairly uniform. When the body is under physiological stress, whether from iron deficiency, vitamin deficiency, chronic inflammation, or active disease, red cells begin to vary more in their dimensions. RDW rises when that variability increases.

The value appears on every routine complete blood count, which means it is already in your results, at no additional cost and requiring no extra blood. No referral to a specialist test is needed. It has been sitting in your report, alongside everything else, each time your bloods have been taken.

What the 2026 Review Found

A systematic review and meta-analysis published in BMC Gastroenterology on 27 July 2026 (Khalil Y, Elhodhod MA, Barghash M, and colleagues; pubmed:42509537) pooled the available studies on RDW across both Crohn's disease and ulcerative colitis, drawing on searches of PubMed, Web of Science, and Scopus.

The results were consistent across both conditions. People with Crohn's disease had significantly elevated RDW compared to healthy controls, with a mean difference of +2.2. People with ulcerative colitis showed a smaller but still significant elevation, with a mean difference of +1.36. Both findings point in the same direction: IBD is associated with measurably higher red cell size variability than is seen in people without the condition.

Active Disease Versus Remission

The more clinically useful finding was what happened when the researchers compared RDW during active disease against RDW during remission. In both Crohn's disease and ulcerative colitis, RDW was significantly higher during active flares than during periods of disease quiescence.

For Crohn's disease, the review identified a specific threshold. An RDW value above 14% distinguished active disease from remission with a sensitivity of 86% and a specificity of 78%. In plain terms: at that cutoff, the test correctly identified active disease in 86 out of 100 patients with active disease, and correctly identified remission in 78 out of 100 patients who were in remission.

These are not perfect numbers, and no single biomarker in IBD is. But they are meaningful, particularly given that this accuracy is achieved using information that is already present in a standard blood count.

Why This Matters to Patients

For anyone living with IBD, the question of whether your disease is currently active or controlled is one of the most practically significant questions in daily life. It shapes decisions about activity, diet, medication adherence, and when to seek clinical review. Many of the existing tools for assessing disease activity require colonoscopy, imaging, or faecal calprotectin testing. RDW does not.

The NHS describes blood tests, including full blood counts, as a standard part of IBD investigation and monitoring, used to assess inflammation levels, check for anaemia, and monitor nutritional status (NHS, IBD diagnosis). What this 2026 review adds is evidence that one of the parameters already on that routine blood count, RDW, carries independent signal about where your disease stands.

The authors described RDW as a potentially "practical and valuable biomarker" for IBD evaluation precisely because it requires no additional testing infrastructure, no additional cost, and no additional specimen.

Clinical Context and Limitations

A systematic review is a synthesis of existing studies, and the quality of a meta-analysis depends on the quality and size of the underlying studies. The authors' conclusions are appropriately described as the data supporting RDW's utility, not establishing it as a definitive standalone diagnostic tool. RDW is one value among many. It does not replace CRP, calprotectin, or endoscopy in assessing IBD. It is more accurately understood as a potentially useful addition to the picture that routine monitoring already provides.

What the review points to is not a new test, but a new reason to look carefully at a number that has always been there. If RDW rises between two blood tests, that may be a signal worth discussing with your IBD team. Whether it is acting as a marker of inflammation, iron status, nutritional depletion, or some combination, is a question for clinical interpretation, not inference from a number alone.

What to Take from This

RDW is not a diagnostic breakthrough. It is a refinement of what routine blood monitoring can tell us. For IBD patients who feel a flare coming, or who are trying to understand whether their treatment is working, knowing that this commonly overlooked blood count parameter correlates with disease activity is genuinely useful information to bring to a clinical conversation.

Your blood results are yours. The RDW is in there. It is worth asking your gastroenterologist or IBD nurse what yours has been doing.